Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × Cytidine Triphosphate × Clear all
NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡